Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria

Brain Research

Volumn 975, Issue 1-2, 2003, Pages 214-221

  Fonck, Carlos ^a,b   Baudry, Michel ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Dopaminergic; FCCP; Free radical; MPP+; MPTP; Parkinson's disease; Rotenone; Synaptosome

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; DOPAMINE; FREE RADICAL; LUCIFERASE; LUCIFERIN; MANGANESE N,N' ETHYLENEBIS(3 METHOXYSALICYLIDENEAMINE); OXIDOREDUCTASE INHIBITOR; OXYGEN RADICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; ROTENONE; SCAVENGER; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BRAIN MITOCHONDRION; BRAIN SYNAPTOSOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; ENZYME SUBSTRATE COMPLEX; FLUORESCENCE; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TELENCEPHALON;

EID: 0038066355     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02675-1     Document Type: Article

References (46)

1. Adams J.D. Jr., Klaidman L.K., Leung A.C. MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes. Free Radic. Biol. Med. 15:1993;181-186.
2. Baudry M., Etienne S., Bruce A., Palucki M., Jacobsen E., Malfroy B. Salen-manganese complexes are superoxide dismutase-mimics. Biochem. Biophys. Res. Commun. 192:1993;964-968.
3. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130.
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
5. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
6. Chan P., DeLanney L.E., Irwin I., Langston J.W., Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57:1991;348-351.
7. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
8. Chiueh C.C., Huang S.J., Murphy D.L. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse. 11:1992;346-348.
9. Choi W.S., Yoon S.Y., Oh T.H., Choi E.J., O'Malley K.L., Oh Y.J. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 57:1999;86-94.
10. Clark J.B., Nicklas W.J. The metabolism of rat brain mitochondria. Preparation and characterization. J. Biol. Chem. 245:1970;4724-4731.
11. Cleeter M.W., Cooper J.M., Schapira A.H. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
12. Corongiu F.P., Dessi M.A., Banni S., Bernardi F., Piccardi M.P., Del Zompo M., Corsini G.U. MPTP fails to induce lipid peroxidation in vivo. Biochem. Pharmacol. 36:1987;2251-2253.
13. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1:1979;249-254.
14. Dawson T., Mandir A., Lee M. Animal models of PD: pieces of the same puzzle? Neuron. 35:2002;219-222.
15. Doctrow H.K., Marcus C.B., Musleh W., Bruce A., Baudry M., Malfroy B. Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Pies H. Antioxidants in Disease Mechanisms and Therapeutic Strategies. 1996;247-269 Academic Press, New York.
16. Eshleman A., Dunigan C., Shamoo A., Eldefrawi M. ATP enhances catecholamine uptake into PC12 cells. Life Sci. 56:1995;1613-1621.
17. Fallon J., Matthews R.T., Hyman B.T., Beal M.F. MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Exp. Neurol. 144:1997;193-198.
18. Ferger B., Spratt C., Teismann P., Seitz G., Kuschinsky K. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur. J. Pharmacol. 360:1998;155-163.
19. Fonck C., Baudry M. Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation. Brain Res. 905:2001;199-206.
20. Friedrich T., Brors B., Hellwig P., Kintscher L., Rasmussen T., Scheide D., Schulte U., Mantele W., Weiss H. Characterization of two novel redox groups in the respiratory NADH:ubiquinone oxidoreductase (complex I). Biochim. Biophys. Acta. 1459:2000;305-309.
21. Gong L., Daigneault E.A., Acuff R.V., Kostrzewa R.M. Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. Neuroreport. 2:1991;544-546.
22. Hallman H., Olson L., Jonsson G. Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur. J. Pharmacol. 97:1984;133-136.
23. Hasegawa E., Takeshige K., Oishi T., Murai Y., Minakami S. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1990;1049-1055.
24. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
25. Javitch J.A., Blaustein R.O., Snyder S.H. [3H]mazindol binding associated with neuronal dopamine uptake sites in corpus striatum membranes. Eur. J. Pharmacol. 90:1983;461-462.
26. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177.
27. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
28. Lotharius J., Dugan L.L., O'Malley K.L. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19:1999;1284-1293.
29. Maragos W.F., Zhu J., Chesnut M.D., Dwoskin L.P. Mitochondrial toxin inhibition of [(3)H]dopamine uptake into rat striatal synaptosomes. Biochem. Pharmacol. 63:2002;1499-1505.
30. Marey-Semper I., Gelman M., Levi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur. J. Neurosci. 5:1993;1029-1034.
31. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature. 311:1984;464-467.
32. Martinovits G., Melamed E., Cohen O., Rosenthal J., Uzzan A. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neurosci. Lett. 69:1986;192-197.
33. Nguyen V.T., Morange M., Bensaude O. Firefly luciferase luminescence assays using scintillation counters for quantitation in transfected mammalian cells. Anal. Biochem. 171:1988;404-408.
34. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
35. Paraidathathu T., de Groot H., Kehrer J.P. Production of reactive oxygen by mitochondria from normoxic and hypoxic rat heart tissue. Free Radic. Biol. Med. 13:1992;289-297.
36. Pearce R.K., Costa S., Jenner P., Marsden C.D. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J. Neural Transm. 106:1999;663-683.
37. Perry T.L., Yong V.W., Clavier R.M., Jones K., Wright J.M., Foulks J.G., Wall R.A. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60:1985;109-114.
38. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
39. Ramsay R.R., Youngster S.K., Gluck M.K., Casida J.E., Singer T.P. Interactions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridium ion (MPP+), and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56:1991;1184-1190.
40. Rong Y., Doctrow S.R., Tocco G., Baudry M. EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc. Natl. Acad. Sci. USA. 96:1999;9897-9902.
41. Rossetti Z.L., Sotgiu A., Sharp D.E., Hadjiconstantinou M., Neff N.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem. Pharmacol. 37:1988;4573-4574.
42. Sanchez-Ramos J.R., Song S., Facca A., Basit A., Epstein C.J. Transgenic murine dopaminergic neurons expressing human Cu/Zn superoxide dismutase exhibit increased density in culture, but no resistance to methylphenylpyridinium-induced degeneration. J. Neurochem. 68:1997;58-67.
43. Sershen H., Reith M.E., Hashim A., Lajtha A. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid. Neuropharmacology. 24:1985;1257-1259.
44. Seyfried J., Soldner F., Kunz W.S., Schulz J.B., Klockgether T., Kovar K.A., Wullner U. Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochem. Int. 36:2000;489-497.
45. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22:2002;7006-7015.
46. Turrens J.F., Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191:1980;421-427.